---
title: "BNT162b2 KP.2 2024–2025 Vaccine Effectiveness Against COVID-19 Hospitalization and ED/UC Visits in"
id: "pubmed-42594639"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42594639"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42594639/"
doi: "10.1016/j.vaccine.2026.129009"
published_at: "2026-09-17T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# BNT162b2 KP.2 2024–2025 Vaccine Effectiveness Against COVID-19 Hospitalization and ED/UC Visits in
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42594639
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42594639/)
- **DOI:** [10.1016/j.vaccine.2026.129009](https://doi.org/10.1016%2Fj.vaccine.2026.129009)
- **Published At:** 2026-09-17T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- This retrospective cohort study estimated real-world **vaccine effectiveness** (VE) of the 2024–2025 formulation **BNT162b2** (KP.2) against COVID-19-associated hospital admission, emergency department (ED), and urgent care (UC) visits in two US states. - Data sources were vaccine registries linked to administrative claims in California and Louisiana within the HealthVerity claims database; the study required ≥1 year continuous enrollment beginning 22 August 2024. - The cohort included 6,256,421 non-immunocompromised adults; 330,565 (5%) received the BNT162b2 KP.2 vaccine. Vaccinated persons were older and had more comorbidities and prior healthcare utilization. - Sixty-six percent of participants had ≥1 underlying medical condition (UMC); most common were obesity (25%), history of immunocompromised conditions (23%), and mental health conditions (19%). - Outcomes used ICD-10-CM code U07.1 for COVID-19-associated ED, UC, or hospitalization encounters. Incidence rates were 25.1 vs 36.3 per 100,000 person-months for vaccinated versus unvaccinated groups. - Adjusted VE (1 − adjusted hazard ratio from Cox models) among all adults was 37% against hospitalization, 12% against ED/UC encounters, and 16% against the combined outcome (ED/UC/hospitalization). - VE estimates were generally similar across age strata (≥65 years; 18–64 years with and without UMCs). Vaccination was associated with lower rates of COVID-19 encounters across groups. - The authors conclude that BNT162b2 KP.2 provided protection against COVID-19-associated ED, UC, and hospitalization during the 2024–2025 respiratory virus season in non-immunocompromised adults, supporting ongoing vaccine recommendations. - The study was registered on ClinicalTrials.gov (NCT06923137). Details on certain design elements, follow-up duration, variant-specific circulation, and sensitivity analyses were not reported in the abstract.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42594639/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42594639%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42594639/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42594639/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42594639/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/c24ab723-7c80-48cd-9c68-022ded852586/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42594639/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42594639/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42594639/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42594639%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42594639%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42594639/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42594639/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42594639/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42594639/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Elsevier Science full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--linkinghub.elsevier.com-ihub-images-elsevieroa.png) Elsevier Science ](https://linkinghub.elsevier.com/retrieve/pii/S0264-410X\(26\)00818-2 "See full text options at Elsevier Science") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42594639/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42594639/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42594639/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42594639/#abstract) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42594639/#similar) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42594639/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42594639/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42594639/#substances) * [ Associated data ](https://pubmed.ncbi.nlm.nih.gov/42594639/#supplemental-data) * [Related information](https://pubmed.ncbi.nlm.nih.gov/42594639/#related-links) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42594639/#linkout) Title & authors Abstract Similar articles Publication types MeSH terms Substances Associated data Related information LinkOut - more resources Observational Study Vaccine Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Vaccine%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Vaccine%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42594639/) . 2026 Sep 17:90:129009. doi: 10.1016/j.vaccine.2026.129009. Epub 2026 Aug 13. # 2024-2025 BNT162b2 KP.2 COVID-19 full season vaccine effectiveness from vaccine registries linked to administrative claims in two states: A cohort study in non-immunocompromised adults [Tara Ahi](https://pubmed.ncbi.nlm.nih.gov/?term=Ahi+T&cauthor_id=42594639)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42594639/#full-view-affiliation-1 "Pfizer Inc., NY, New York, United States. Electronic address: Tara.Ahi@pfizer.com."), [Kathleen M Andersen](https://pubmed.ncbi.nlm.nih.gov/?term=Andersen+KM&cauthor_id=42594639)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42594639/#full-view-affiliation-2 "Pfizer Inc., NY, New York, United States."), [Jazmine S Mateus](https://pubmed.ncbi.nlm.nih.gov/?term=Mateus+JS&cauthor_id=42594639)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42594639/#full-view-affiliation-3 "Genesis Research Group, Hoboken, NJ, United States."), [Tiange Yu](https://pubmed.ncbi.nlm.nih.gov/?term=Yu+T&cauthor_id=42594639)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42594639/#full-view-affiliation-3 "Genesis Research Group, Hoboken, NJ, United States."), [Anan Zhou](https://pubmed.ncbi.nlm.nih.gov/?term=Zhou+A&cauthor_id=42594639)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42594639/#full-view-affiliation-3 "Genesis Research Group, Hoboken, NJ, United States."), [Rajeev M Nepal](https://pubmed.ncbi.nlm.nih.gov/?term=Nepal+RM&cauthor_id=42594639)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42594639/#full-view-affiliation-4 "Pfizer Inc., Collegeville, PA, United States."), [Santiago M C Lopez](https://pubmed.ncbi.nlm.nih.gov/?term=Lopez+SMC&cauthor_id=42594639)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42594639/#full-view-affiliation-4 "Pfizer Inc., Collegeville, PA, United States."), [Laura Puzniak](https://pubmed.ncbi.nlm.nih.gov/?term=Puzniak+L&cauthor_id=42594639)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42594639/#full-view-affiliation-2 "Pfizer Inc., NY, New York, United States.") Affiliations Expand ### Affiliations * 1 Pfizer Inc., NY, New York, United States. Electronic address: Tara.Ahi@pfizer.com. * 2 Pfizer Inc., NY, New York, United States. * 3 Genesis Research Group, Hoboken, NJ, United States. * 4 Pfizer Inc., Collegeville, PA, United States. * PMID: **42594639** * DOI: [ 10.1016/j.vaccine.2026.129009 ](https://doi.org/10.1016/j.vaccine.2026.129009) Free article Item in Clipboard Observational Study # 2024-2025 BNT162b2 KP.2 COVID-19 full season vaccine effectiveness from vaccine registries linked to administrative claims in two states: A cohort study in non-immunocompromised adults Tara Ahi et al. Vaccine. 2026. Free article Show details Display options Display options Format Abstract PubMed PMID Vaccine Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Vaccine%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Vaccine%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42594639/) . 2026 Sep 17:90:129009. doi: 10.1016/j.vaccine.2026.129009. Epub 2026 Aug 13. ### Authors [Tara Ahi](https://pubmed.ncbi.nlm.nih.gov/?term=Ahi+T&cauthor_id=42594639)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42594639/#short-view-affiliation-1 "Pfizer Inc., NY, New York, United States. Electronic address: Tara.Ahi@pfizer.com."), [Kathleen M Andersen](https://pubmed.ncbi.nlm.nih.gov/?term=Andersen+KM&cauthor_id=42594639)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42594639/#short-view-affiliation-2 "Pfizer Inc., NY, New York, United States."), [Jazmine S Mateus](https://pubmed.ncbi.nlm.nih.gov/?term=Mateus+JS&cauthor_id=42594639)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42594639/#short-view-affiliation-3 "Genesis Research Group, Hoboken, NJ, United States."), [Tiange Yu](https://pubmed.ncbi.nlm.nih.gov/?term=Yu+T&cauthor_id=42594639)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42594639/#short-view-affiliation-3 "Genesis Research Group, Hoboken, NJ, United States."), [Anan Zhou](https://pubmed.ncbi.nlm.nih.gov/?term=Zhou+A&cauthor_id=42594639)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42594639/#short-view-affiliation-3 "Genesis Research Group, Hoboken, NJ, United States."), [Rajeev M Nepal](https://pubmed.ncbi.nlm.nih.gov/?term=Nepal+RM&cauthor_id=42594639)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42594639/#short-view-affiliation-4 "Pfizer Inc., Collegeville, PA, United States."), [Santiago M C Lopez](https://pubmed.ncbi.nlm.nih.gov/?term=Lopez+SMC&cauthor_id=42594639)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42594639/#short-view-affiliation-4 "Pfizer Inc., Collegeville, PA, United States."), [Laura Puzniak](https://pubmed.ncbi.nlm.nih.gov/?term=Puzniak+L&cauthor_id=42594639)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42594639/#short-view-affiliation-2 "Pfizer Inc., NY, New York, United States.") ### Affiliations * 1 Pfizer Inc., NY, New York, United States. Electronic address: Tara.Ahi@pfizer.com. * 2 Pfizer Inc., NY, New York, United States. * 3 Genesis Research Group, Hoboken, NJ, United States. * 4 Pfizer Inc., Collegeville, PA, United States. * PMID: **42594639** * DOI: [ 10.1016/j.vaccine.2026.129009 ](https://doi.org/10.1016/j.vaccine.2026.129009) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID ## Abstract **Background:** Data on effectiveness of COVID-19 vaccinations during the 2024-2025 respiratory season are limited, particularly among those with underlying medical conditions (UMC). We estimated BNT162b2 KP.2 vaccine effectiveness (VE) against COVID-19-associated hospital admission, emergency department (ED), and urgent care (UC) visits in two U.S. states. **Methods:** Retrospective cohort study of non-immunocompromised adults living in Louisiana or California, with ≥1 year prior continuous enrollment in insurance plans contributing to the HealthVerity claims database beginning August 22, 2024. The effectiveness of BNT162b2 KP.2 vaccine (2024-2025 formulation, hereafter referred to as BNT162b2), measured as a time-varying exposure against hospital admission, ED, or UC encounters with International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) code U07.1 was calculated as 1 - adjusted hazard ratio using Cox proportional hazard models adjusted for age group, sex, state, insurance payor, presence or absence of UMCs, and pre-index healthcare utilization. Stratifications included those aged 65 years and older, those aged 18-64 years with UMCs, and those aged 18-64 years without UMCs. **Results:** The cohort included 6,256,421 individuals (93% California, 7% Louisiana); 330,565 (5%) received the BNT162b2 vaccine. Vaccinated individuals were older and had more comorbidities, wellness visits, and prior influenza vaccination. Overall, 66% of the study population had ≥1 UMC; the most prevalent conditions were obesity (25%), history of immunocompromised conditions (23%), and mental health conditions (19%). COVID-19-related encounter rates for ED, UC or hospitalization were lower among vaccinated compared to unvaccinated persons (25.1 vs 36.3 per 100,000 person-months). Among all adults, VE was 37% against hospitalization, 12% against ED/UC encounters, and 16% against ED/UC/hospitalization encounters. Results were similar across age groups and UMCs. **Conclusions:** BNT162b2 provided protection against COVID-19-associated outcomes of ED, UC or hospitalization among non-immunocompromised U.S. adults, including those with UMCs, over the course of the 2024-2025 respiratory virus season, supporting continued vaccine recommendations. **Registration:** This study was posted on clinicaltrials.gov prior to analyses ([NCT06923137](http://clinicaltrials.gov/show/NCT06923137 "See in ClinicalTrials.gov")). **Keywords:** COVID-19; Real-world evidence; Risk reduction; Vaccine effectiveness. Copyright © 2026 The Authors. Published by Elsevier Ltd.. All rights reserved. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Similar articles * [ 2024-2025 BNT162b2 COVID-19 vaccine effectiveness in non-immunocompromised adults: mid-season estimates from vaccine registries in two states linked to administrative claims. ](https://pubmed.ncbi.nlm.nih.gov/40712320/) Andersen KM, Ahi T, Mateus JS, Yu T, Zhou A, Lopez SMC, Puzniak L.Andersen KM, et al.Vaccine. 2025 Aug 30;62:127534. doi: 10.1016/j.vaccine.2025.127534. Epub 2025 Jul 24.Vaccine. 2025.PMID: 40712320 * [ BNT162b2 XBB.1.5-Adapted Single Dose Vaccine Uptake and Effectiveness in Children Aged 5-17 Years Using Linked Claims and Vaccine Registries in California and Louisiana. ](https://pubmed.ncbi.nlm.nih.gov/40818804/) Andersen KM, McColgan MD, Mateus JS, Yu T, Zhou A, Puzniak L, Lopez SMC.Andersen KM, et al.J Pediatr. 2025 Nov;286:114778. doi: 10.1016/j.jpeds.2025.114778. Epub 2025 Aug 14.J Pediatr. 2025.PMID: 40818804Clinical Trial. * [ Estimated Effectiveness of the BNT162b2 XBB Vaccine Against COVID-19. ](https://pubmed.ncbi.nlm.nih.gov/38913355/) Tartof SY, Slezak JM, Frankland TB, Puzniak L, Hong V, Ackerson BK, Stern JA, Zamparo J, Simmons S, Jodar L, McLaughlin JM.Tartof SY, et al.JAMA Intern Med. 2024 Aug 1;184(8):932-940. doi: 10.1001/jamainternmed.2024.1640.JAMA Intern Med. 2024.PMID: 38913355Free PMC article. * [ Estimated Effectiveness of 2024-2025 COVID-19 Vaccines in Adults. ](https://pubmed.ncbi.nlm.nih.gov/42295789/) Wiegand RE, Payne AB, Mak J, Chickery S, Reese SE, Klein NP, Grannis SJ, Ong TC, Rowley EAK, DeSilva M, Dascomb K, Irving SA, Zerbo O, Hansen JR, Block L, Jacobson KB, Dixon BE, Rogerson CM, Duszynski TJ, Fadel WF, Barron MA, Mayer D, Chavez C, Yang DH, Ball SW, McEvoy CE, Akinsete OO, Sheffield T, Bride D, Arndorfer J, Van Otterloo J, Naleway AL, Natarajan K, Najdowski M, Ciesla AA, Kautz A, DeCuir J, Link-Gelles R.Wiegand RE, et al.JAMA Intern Med. 2026 Aug 1;186(8):976-986. doi: 10.1001/jamainternmed.2026.1936.JAMA Intern Med. 2026.PMID: 42295789 * [ Real-World Effectiveness of RSVpreF and RSVpreF3 Vaccines in Preventing Hospitalization and Emergency Department Visits Associated With Respiratory Syncytial Virus in Older Adults: A Meta-analysis. ](https://pubmed.ncbi.nlm.nih.gov/41705791/) Sumsuzzman DM, Shi C, Moghadas SM.Sumsuzzman DM, et al.Clin Infect Dis. 2026 May 20;82(5):e1104-e1111. doi: 10.1093/cid/ciag107.Clin Infect Dis. 2026.PMID: 41705791Free PMC article. [ See all similar articles ](https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed&from_uid=42594639) ## Publication types * Observational Study Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Observational+Study%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Observational+Study) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42594639/) ## MeSH terms * Adolescent Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Adolescent%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Adolescent) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42594639/) * Adult Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Adult%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Adult) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42594639/) * Aged Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Aged%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Aged) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42594639/) * BNT162 Vaccine* / immunology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22BNT162+Vaccine%2Fimmunology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=BNT162+Vaccine) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42594639/) * COVID-19 Vaccines* / administration & dosage Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22COVID-19+Vaccines%2Fadministration+and+dosage%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=COVID-19+Vaccines) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42594639/) * COVID-19 Vaccines* / immunology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22COVID-19+Vaccines%2Fimmunology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=COVID-19+Vaccines) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42594639/) * COVID-19* / epidemiology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22COVID-19%2Fepidemiology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=COVID-19) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42594639/) * COVID-19* / immunology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22COVID-19%2Fimmunology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=COVID-19) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42594639/) * COVID-19* / prevention & control Actions * [ Search in PubMed ](https
## Related Clinical Research

- [Pennsylvania reports third measles-related death amid ongoing outbreak; other health headlines](https://medichelpline.com/clinical-feed/stat-news-2-pennsylvania-records-third-measles-related-death-amid-outbreak.md)
- [Medical groups, Vaccine Integrity Project issue joint RSV, Covid-19, and influenza vaccine guidanc](https://medichelpline.com/clinical-feed/stat-news-0-doctors-groups-release-vaccination-guidelines-ahead-of-respiratory-illness.md)
- [Incidence of RSV in Adults ≥50 Years in the Upper Midwest After COVID-19: Community Cohort Finding](https://medichelpline.com/clinical-feed/bmj-open-6-incidence-of-respiratory-syncytial-virus-in-adults-50-years-during-and.md)
- [Prevalence and determinants of vaccine hesitancy in Buenos Aires: results of a 2025 household surv](https://medichelpline.com/clinical-feed/pubmed-42603507.md) (DOI: 10.1016/j.vaccine.2026.129045)
- [Pharmacist-Provided Vaccination to Expand Adult Immunization in LMICs](https://medichelpline.com/clinical-feed/pubmed-42585811.md) (DOI: 10.1016/j.vaccine.2026.129004)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.